tiprankstipranks
Bicara Therapeutics initiated with a Not Rated at Goldman Sachs
PremiumThe FlyBicara Therapeutics initiated with a Not Rated at Goldman Sachs
3M ago
Bicara Therapeutics Reports Strong IPO and Clinical Advancements
Premium
Company Announcements
Bicara Therapeutics Reports Strong IPO and Clinical Advancements
3M ago
Bicara Therapeutics reports Q3 EPS ($1.60), consensus (46c)
Premium
The Fly
Bicara Therapeutics reports Q3 EPS ($1.60), consensus (46c)
3M ago
Bicara Therapeutics initiated with an Overweight at Morgan Stanley
PremiumThe FlyBicara Therapeutics initiated with an Overweight at Morgan Stanley
5M ago
Bicara Therapeutics initiated with a Buy at Stifel
Premium
The Fly
Bicara Therapeutics initiated with a Buy at Stifel
5M ago
Bicara Therapeutics initiated with a Buy at TD Cowen
Premium
The Fly
Bicara Therapeutics initiated with a Buy at TD Cowen
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100